Publications by authors named "G Morabito"
Adherence to perindopril/amlodipine/atorvastatin combination according to the administration strategy.
Eur Heart J Qual Care Clin Outcomes
January 2025
Aims: To compare adherence to perindopril/amlodipine/atorvastatin combination administrated as a polypill (one pill) vs separate tablets.
Methods: Using the healthcare utilization database of Lombardy (Italy), 1 110 patients who received the perindopril/amlodipine/atorvastatin polypill during 2019-2021 were matched with 1 110 patients prescribed the same combination in separate tablets or as two antihypertensive drugs in a single tablet and the lipid-lowering drug tablet separately. Adherence to treatment was assessed over the year after the first perindopril/amlodipine/atorvastatin dispensation as the proportion of the follow-up days covered by prescription (PDC).
Article Synopsis
- The study investigates the impact of using the Poisson regression model to control for immortal time bias when dealing with time-varying risks in exposure-outcome relationships.
- Small variations in event risk over time significantly distorted the estimates of exposure effects, leading to biased results regardless of the actual exposure effect.
- Researchers recommend adjusting for outcome risk trends in Poisson models or considering alternative models to avoid these biases.
Article Synopsis
- A study analyzed the long-term cost-effectiveness of a single-pill combination (SPC) of three antihypertensive drugs compared to a two-pill combination in Italy, finding that the SPC improves medication adherence.
- The study evaluated data from over 95,000 patients using advanced modeling to assess costs and life expectancy, showing that the SPC resulted in an increase of 0.86 years of life at a slightly lower mean cost.
- The savings from reduced hospitalization costs outweighed the higher drug costs of the SPC, establishing it as a more cost-effective treatment strategy.
Article Synopsis
- The COVID-19 pandemic worsened heart failure (HF)-related mortality, but it's unclear how much was due to healthcare changes versus the virus itself.
- A study analyzed healthcare databases in Lombardy, Italy, identifying new HF patients from 2018 to 2021 to assess treatment use and mortality outcomes.
- Findings showed that during the pandemic, there was decreased use of key HF treatments and an overall increased risk of mortality among HF patients, primarily due to SARS-CoV-2 infection.
Context: Patients with diabetes are at increased risk of dying from liver-related events, but little is known on whether this increased risk has changed in recent years.
Objective: The aim of the present study is to describe time trends in cause-specific liver-related mortality in people with and without diabetes from the general Italian population.
Methods: Data were retrieved from the health care utilization databases of Lombardy, a region of Italy that accounts for about 16% (almost 10 million) of its population.